髙橋 悟 たかはし さとる 先生

来歴等

略歴

1985年 群馬大学医学部医学科 卒業
1987年 東京大学 助手（医学部附属病院泌尿器科）
1988年 国家公務員共済連合会虎ノ門病院 泌尿器科医員
1989年 都立駒込病院 泌尿器科医員
1993年 米国メイヨークリニック 泌尿器科
2000年 東京大学医学部附属病院 泌尿器科 講師
2003年 東京大学医学部附属病院 泌尿器科 助教授
2005年 日本大学医学部 泌尿器科学系 泌尿器科学分野 主任教授
2020年 日本大学医学部附属板橋病院 副病院長
2021年 日本大学医学部附属板橋病院 病院長

論文

• 1.Transurethral ultrasound-guided laser-induced prostatectomy (TULIP) for benign prostatic hyperplasia: Clinical utility at one-year follow-up and imaging analysis. Urology 43:802-807, 1994.

  Takahashi S, Homma Y, Minowada S, Aso Y

• 2.Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res. 54:3574-3579, 1994.

  Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB

• 3.Frequent loss of heterozygosity at 7q31.1 in prostate cancer is associated with tumor aggressiveness and progression. Cancer Res. 55:4114-4119, 1995.

  Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thibodeau SN, Jenkins RB

• 4.Cytogenetic analysis of prostate carcinoma by fluorescence in situ hybridization. Int. J. Urol. 2:215-223, 1995.

  Takahashi S, Jenkins RB, Lieber MM

• 5.Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathologic stage C (pT3N0M0) prostate carcinoma. Clin. Cancer Res. 2:137-145, 1996.

  Takahashi S, Alcaraz A, Brown JA, Borell TJ, Herath JF, Bergstralh EJ, Lieber MM, Jenkins RB

• 6.Urodynamic analysis of age-related changes of α1-adrenoceptor responsiveness in female beagle dogs. J. Urol. 156:1485-1488, 1996.

  Takahashi S, Moriyama N, Yamazaki R, Kawabe K

• 7.Electromyographic study of the striated urethral sphincter in type 3 stress incontinence: evidence of myogenic-dominant damages. Urology 56:946-950, 2000.

  Takahashi S, Homma Y, Fujishiro T, Hosaka Y, Kitamura T, Kawabe K

• 8.Power Doppler ultrasonography-directed prostate biopsy in men with elevated serum PSA levels: An evaluation of the clinical utility and limitations. Urology 60:248-252, 2002.

  Takahashi S, Yamada Y, Homma Y, Horie S, Hosaka Y, Kitamura T

• 9.EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer. Int. J. Cancer 106:310-315, 2003.

  Takahashi S, Urano T, Tsuchiya F, Fujimura T, Kitamura T, Ouchi Y, Muramatsu M, Inoue

• 10.Combination Chemotherapy of Docetaxel, Ifosfamide and Cisplatin (DIP) in Patients with Metastatic Urothelial Cancer: A Preliminary Report. Jpn. J. Clin. Oncol. 35:79-83, 2005.

  Takahashi S, Suzuki M, Kume H, Matsumoto S, Okamoto N, Nishimatsu H, Tomita K, and Kitamura T

• 11.Function of the lower urinary tract in mice lacking α1d-adrenoceptor. J. Urol. 174:370-374, 2005. (* Corresponding author)

  Chen Q, Takahashi S*, Zhong S, Hosoda C, Zheng H-Y, Ogushi T, Fujimura T,　Ohta N, Tanoue A, Tsujimoto G, Kitamura T

• 12.Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma. Cancer Res. 65:3700-3706, 2005.

  Ogushi T, Takahashi S, Takeuchi T, Urano T, Ouchi Y, Kitamura T, Muramatsu M, Inoue S

• 13. The clinical efficacy of an a α1a/d-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int. J. Urol. 13:15-20, 2006.

  Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominaga T, Kitamura T

• 14.Periurethral injection of sustained-release basic fibroblast growth factor (FGF) Improves sphincteric contractility of the rat urethra denervated by botulinum-A toxin. J. Urol. 176:819-823, 2006.

  Takahashi S, Chen Q, Ogushi T, Fujimura T, kumagai J, Matsumoto S, Hijikata S, Tabata Y, and Kitamura T

• 15.Increased expression of Estrogen-Related Receptor α (ERRα) is a negative prognostic predictor in human prostate cancer. Int. J. Cancer ,120:2325-2330, 2007 (* Corresponding author)

  Fujimura T, Takahashi S*, Urano T, Kumagai J, Ogushi T, Horie-Inoue K, Ouchi Y, Kitamura T, Muramatsu M, Inoue S

• 16.Transvaginal Mesh (TVM) Reconstruction with TVT/TOT Sling for Vaginal Proslapse Concurrent with Stress Urinary Incontinence. Aktuel Urol,41:S20-S23, 2010.1.

  Takahashi S, Obinata D, Sakuma T, Matsui T, Takenobu Y, Igarashi T, Yoshizawa T, Sato K, Mochida J, Sugimoto S

• 17.Differential expression of estrogen-related receptors β and γ (ERRβ and ERRγ) and their clinical significance in human prostate cancer. Cancer Science，101(3):646-51, 2010.3.

  Fujimura T, Takahashi S, Urano T, Ijichi N, Ikeda K, Kumagai J, Murata T, Takayama K, Horie-Inoue K, Ouchi Y, Muramatsu M, Homma Y, Inoue S

• 18.Tension-free Vaginal Mesh Procedure for Pelvic Organ Prolapse: Single Center Experience of 310 Cases with One Year Follow-up. Int J Urol, 17:353-358, 2010.4.

  Takahashi S,　Obinata D, Sakuma T, Nagane Y, Sato K, Mochida J, Ichinose T, Yamaguchi K

• 19.Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer. Cancer Sci, 103(2):176-80, 2012.2.

  Fujimura T, Takahashi S, Urano T, Tanaka T, Zhang W, Azuma K, Takayama K, Obinata D, Murata T, Horie-Inoue K, Kodama T, Ouchi Y, Homma Y, Inoue S

• 20.Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer.　Int J Cancer, 130(5): 1021-8, 2012.3.1.

  Obinata D, Takayama K, Urano T, Murata T, Kumagai J, Fujimura T, Ikeda K, Horie-Inoue K, Homma Y, Ouchi Y, Takahashi S, Inoue S

• 21.14-3-3ζ, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival. Clin Cancer Res, 18:5617-5627,2012.10.15.

  Murata T, Takayama K, Urano T, Fujimura T, Ashikari D, Obinata D, Horie-Inoue K, Takahashi S, Ouch, Y, Homma Y, and Inoue S

• 22.Lower urinary tract symptoms in female patients with pelvic organ prolapse: efficacy of pelvic floor reconstruction. Int J Urol, 21(3):301-7，2014.

  Obinata D, Yamaguchi K, Ito A, Murata Y, Ashikari D, Igarashi T, Sato K, Mochida J, Yamanaka Y, Takahashi S

• 23.Expression of androgen and estrogen signaling components and stem cell markers to predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer. Clin Cancer Res, 20(17):4625-35, 2014.9.1.

  Fujimura T, Takahashi S, Urano T, Takayama K, Sugihara T, Obinata D, Yamada Y, Kumagai J, Kume H, Ouchi Y, Inoue S, Homma Y

• 24.Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth. Cancer Sci,105(10):1272-8,2014.10.

  Obinata D, Ito A, Fujiwara K, Takayama K, Ashikari D, Murata Y, Yamaguchi K, Urano T, Fujimura T, Fukuda N, Soma M, Watanabe T, Nagase H, Inoue S, Takahashi S

• 25.CtBP2 modulates the androgen receptor to promote prostate cancer progression. Cancer Res, 74(22):6542-53, 2014.11.15.

  Takayama K, Suzuki T, Fujimura T, Urano T, Takahashi S, Homma Y, Inoue S

• 26.There is a possibility that the urethra opens actively and independently by the lateral movement of the urethral muscles themselves.　Int J Urol,22(6):615, 2015.6.

  Watanabe H, Takahashi S, Ukimura O

• 27.Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial. Int J Urol, 22(7):684-8, 2015.7.

  Yokoyama O, Yamaguchi A, Yoshida M, Yamanishi T, Ishizuka O, Seki N, Takahashi S, Yamaguchi O, Higo N, Minami H, Masegi Y

• 28.Corrigendum: TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat Commun, 6:8219,2015.9.25.

  Takayama K, Misawa A, Suzuki T, Takagi K, Hayashizaki Y, Fujimura T, Homma Y, Takahashi S, Urano T, Inoue S

• 29.Clinical Guideline for Female Lower Urinary Tract Symptoms. GUIDELINE. LUTS,8：5-29，2016.1.

  Takahashi S, Takei M, Nishizawa O, Yamaguchi O, Kato K, Gotoh M, Yoshimura Y, Takeyama M, Ozawa H, Shimada M, Yamanishi T, Yoshida M, Tomoe H, Yokoyama O, Koyama M

• 30.Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration. Eur J Cancer, 57: 39-49,2016.4.

  Obinata D, Takada S, Takayama K, Urano T, Ito A, Ashikari D, Fujiwara K, Yamada Y, Murata T, Kumagai J, Fujimura T, Ikeda K, Horie-Inoue K,Homma Y, Takahashi S, Inoue S

• 31.Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer. Oncogene. 9; 36(45):6272-6281, 2017.

  Ashikari D, Takayama K, Tanaka T, Suzuki Y, Obinata D, Fujimura T, Urano T, Takahashi S, Inoue S

• 32.TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer. Oncogene 37(16)2165-80.2018.

  Takayama KI, Suzuki T, Tanaka T, Fujimura T, Takahashi S, Urano T, Ikeda K, Inoue S

• 33.COBLL1 modulates cell morphology and facilitates androgen receptor genomic binding in advanced prostate cancer. Proc Natl Acad Sci of USA, 115(19): 4975-80.2018.

  Takayama KI, Suzuki T, Fujimura T, Takahashi S, Inoue S

著書

• 1.よくわかる前立腺の病気（岩波アクティブ新書）

• 2.40歳からの女性の医学　骨盤臓器脱（岩波書店）

• 3.スーパー図解　女性の頻尿・尿失禁（法研）

• 4.ウルトラ図解　前立腺の病気（法研）

特許

• 1.新規ＰＩポリアミド．2012.（特願2012-106382）

  大日方大亮，髙橋　悟, 福田　昇, 藤原恭子

• 2.新規ＰＩポリアミド．2013.（特願2013-048126）

  大日方大亮，髙橋　悟, 藤原恭子，井上　聡，高山賢一

• 3. 前立腺癌の判定、治療選択方法、予防又は治療剤．2014.11.21．（特願2014-237008）

  芦苅大作, 髙橋　悟, 大日方大亮, 井上　聡, 髙山賢一. 学校法人日本大学

受賞

• 1.平成7年度, 鈴木泌尿器医学振興財団助成. 研究課題：潜在並びに臨床前立腺癌における染色体欠失の比較検討.

• 2.平成12年度, 財団法人神澤医学研究振興財団研究助成.研究課題：外尿道括約筋における塩基性繊維芽細胞成長因子（bFGF）投与の効果.

• 3.平成13年度, 第1回オルガノン泌尿器科研究助成（基礎研究部門） 研究課題：前立腺肥大症におけるエストロゲン受容体, エストロゲン応答遺伝子efp (estrogen responsive finger protein gene)の役割.

• 4.平成13年度, 山口内分泌疾患研究振興協会研究助成. 研究課題：前立腺癌とエストロゲン応答遺伝子発現調節.

• 5.平成13年度, 財団法人磁気健康科学研究振興財団研究助成. 研究課題：在宅磁気刺激療法の切迫性尿失禁、頻尿に対する治療効果の検討ー無作為対照比較試験.

• 6.平成18年度, 第19回日本老年泌尿器科学会学会賞（医師部門）

• 7. 2011年度, 第3回ロート女性健康科学研究会助成． 研究テーマ：女性骨盤臓器脱症によるQOLへの影響解析と治療指針の作成

その他

• 【テレビ出演】 「きょうの健康」，「名医にQ」，「あさイチ」,「ゆうどきネットワーク」,「チョイス＠病気になったとき」(NHK）,「たけしのみんなの家庭の医学」(テレビ朝日），「世界一受けたい授業」(日本テレビ）他